SCL

STEPAN CO

Basic Materials | Small Cap

$0.63

EPS Forecast

$551.7

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2024-12-31
EX-99.1 2 scl-ex991_53.htm EX-99.1 scl-ex991_53.htm

 

 

Exhibit 99.1

 

Stepan Reports Fourth Quarter and Full Year 2019 Results

 

Northfield, Illinois, February 20, 2020 -- Stepan Company (NYSE: SCL) today reported:

 

Fourth Quarter Highlights

 

 

Reported net income was $22.0 million, or $0.95 per diluted share versus $24.0 million, or $1.03 per diluted share, in the prior year.  Adjusted net income* was $25.7 million, or $1.10 per diluted share versus $19.5 million, or $0.84 per diluted share, in the prior year.  

 

 

 

Surfactant operating income was $33.9 million versus $29.1 million in the prior year. This increase was attributable to insurance recovery related to the Company’s first quarter 2019 equipment failure in Ecatepec, Mexico and margin improvement in Latin America and Europe.  These items were partially offset by lower sales volume due to lower demand and year end inventory reductions in our distribution channel and higher unit overhead costs in Singapore due to unfavorable production timing differences.  Global Surfactant sales volume was flat versus the prior year.

 

 

 

Polymer operating income was $11.4 million versus $9.5 million in the prior year. This increase was mostly attributable to higher volume and improved margins.  Global Polymer sales volume increased 3% versus the prior year.  Global rigid polyol volume growth of 7% more than offset lower volume in the phthalic anhydride end market.  

 

 

 

Specialty Product operating income was $5.0 million versus $5.1 million in the prior year.  This slight decrease reflects unfavorable order timing differences within our flavor business largely offset by improved margins within our medium chain triglycerides (MCTs) product line.

 

 

Full Year Highlights

 

 

Reported net income was $103.1 million, or $4.42 per diluted share, versus $111.1 million, or $4.76 per diluted share, in the prior year.  Adjusted net income* was $119.4 million, or $5.12 per diluted share, a 7% increase versus $111.7 million, or $4.79 per diluted share, in the prior year.  

 

 

 

The Surfactant segment delivered operating income of $122.8 million, an 8% decline versus prior year driven by North America. The key drivers in the U.S. were lower Personal Care commodity volume due to one key customer losing an important business and lower demand and year end inventory adjustments in the distribution channel.  The Polymer segment delivered $69.6 million of operating income, a 5% increase versus prior year.  Specialty Product operating income was $16.4 million versus $11.7 million in the prior year.

 

 

 

Total Company sales volume decreased 2% versus the prior year.  Sales volume growth within the Polymer and Specialty Product segments was offset by a 3% decline in Surfactant sales volume, or a 2% decline excluding the exit from the sulfonation business in Germany.

 

 

 

The Company had negative net debt at year-end as cash balances of $315 million exceeded total debt of $222 million.

 

1


 

 

The effect of foreign currency translation negatively impacted net income by $2.0 million, or $0.08 per diluted share, versus the prior year.

 

 

 

As disclosed in the first quarter of 2019, the Company elected to change its method of accounting for U.S. inventories from the last in, first out (LIFO) basis to the first in, first out (FIFO) basis.  The Company has retrospectively applied this change to its prior year financial statement comparables and denoted impacted prior year columns “As Adjusted”.  The net impact of changing from the LIFO method to the FIFO method on prior year results was $3.0 million of additional expense recognition in the fourth quarter and $1.6 million of additional expense recognition for full year 2018.  

 

 

*

Adjusted net income is a non-GAAP measure which excludes deferred compensation income/expense, cash-settled stock appreciation rights (SARs), as well as other significant and infrequent/non-recurring items. See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share.

 

 

“Despite significant challenges during the year, driven by the equipment failure in Ecatepec, the wet weather in the U.S. farm belt, the sulfonation exit in Germany and FX headwinds, the Company exceeded its 2018 record full year adjusted net income and grew adjusted EPS 7%,” said F. Quinn Stepan, Jr., Chairman, President and Chief Executive Officer.  “For the quarter, Surfactant earnings were up due to the insurance recovery in Mexico and improved margins.  The Polymer business had a good fourth quarter driven by global rigid polyol growth of 7%.  Specialty Products income was down slightly due to customer order patterns but was up significantly on a full year basis.”  

 

Financial Summary

 

 

Three Months Ended

December 31

 

 

Twelve Months Ended

December 31

 

($ in thousands, except per share data)

2019

 

 

2018                        As Adjusted

 

 

%

Change

 

 

2019

 

 

2018                        As Adjusted

 

 

%

Change

 

Net Sales

$

444,990

 

 

$

466,659

 

 

 

(5

)%

 

$

1,858,745

 

 

$

1,993,857

 

 

 

(7

)%

Operating Income (1)

$

28,491

 

 

$

35,451

 

 

 

(20

)%

 

$

127,260

 

 

$

149,265

 

 

 

(15

)%

Net Income (1)

$

22,038

 

 

$

23,957

 

 

 

(8

)%

 

$

103,129

 

 

$

111,117

 

 

 

(7

)%

Earnings per Diluted Share (1)

$

0.95

 

 

$

1.03

 

 

 

(8

)%

 

$

4.42

 

 

$

4.76

 

 

 

(7

)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted Net Income (1) (2)

$

25,692

 

 

$

19,482

 

 

 

32

%

 

$

119,387

 

 

$

111,652

 

 

 

7

%

Adjusted Earnings per Diluted Share (1) (2)

$

1.10

 

 

$

0.84

 

 

 

31

%

 

$

5.12

 

 

$

4.79

 

 

 

7

%

 

 

(1)

The 2018 amounts for the noted line items have been retrospectively changed from the amounts originally reported as a result of the Company’s first quarter 2019 change in method of accounting for U.S. inventory valuation from LIFO to FIFO.

 

(2)

See Table II for reconciliations of non-GAAP adjusted net income and earnings per diluted share.

 

 

 

Summary of Fourth Quarter Adjusted Net Income Items

 

Adjusted net income excludes non-operational deferred compensation income/expense, cash-settled SARs and other significant and infrequent/non-recurring items.

 

 

Deferred Compensation:  The current year fourth quarter reported net income includes $1.5 million of after tax expense versus $3.4 million of after-tax income in the prior year.

 

2


 

Cash-Settled SARs:  These management incentive instruments provide cash to participants equal to the appreciation on the price of specified shares of Company stock over a specified period of time.  Because income or expense is recognized merely on the movement in the price of Company stock it has been excluded, similar to deferred compensation, to arrive at adjusted net income.  The current year fourth quarter includes $0.3 million of after-tax expense versus $1.2 million of after-tax income in the prior year.

 

 

Business Restructuring:  The current year fourth quarter reported net income includes $0.8 million of after-tax decommissioning expense primarily related to the Company’s prior year Canadian plant closure and Germany sulfonation shutdown versus $0.2 million of after-tax expense in the prior year.  

 

 

Environmental Remediation:  The current year quarter reported net income includes $1.1 million of after-tax expense versus no expense recognition in the prior year.  The current year expense primarily relates to higher anticipated environmental remediation costs associated with the Company’s formerly-owned site in Wilmington, Massachusetts.

 

Percentage Change in Net Sales

 

Net sales decreased 5% in the year-over-year fourth quarter due to a 4% decline in global selling prices, mainly attributable to the pass-through of lower raw material costs, and the unfavorable impact of foreign currency translation.  Polymer sales volume growth of 3% more than offset slight declines in Surfactant and Specialty Product volume.    

 

 

Three Months Ended

December 31, 2019

 

 

Twelve Months Ended

December 31, 2019

 

Volume

 

 

 

 

 

(2

)%

Selling Price

 

 

(4

)%

 

 

(3

)%

Foreign Translation

 

 

(1

)%

 

 

(2

)%

Total

 

 

(5

)%

 

 

(7

)%

 

Segment Results

 

 

 

Three Months Ended

December 31

 

 

Twelve Months Ended

December 31

 

($ in thousands)

 

2019

 

 

2018

 

 

%

Change

 

 

2019

 

 

2018

 

 

%

Change

 

Net Sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Surfactants

 

$

309,974

 

 

$

323,224

 

 

 

(4

)%

 

$

1,272,723

 

 

$

1,385,932

 

 

 

(8

)%

Polymers

 

$

116,443

 

 

$

122,974

 

 

 

(5

)%

 

$

512,347

 

 

$

527,420

 

 

 

(3

)%

Specialty Products

 

$

18,573

 

 

$

20,461

 

 

 

(9

)%

 

$

73,675

 

 

$

80,505

 

 

 

(8

)%

Total Net Sales

 

$

444,990

 

 

$

466,659

 

 

 

(5

)%

 

$

1,858,745

 

 

$

1,993,857

 

 

 

(7

)%

 

 

3


 

 

Three Months Ended

December 31

 

 

Twelve Months Ended

December 31

 

($ in thousands, all amounts pre-tax)

 

2019

 

 

2018

 

 

%

Change

 

 

2019

 

 

2018

 

 

%

Change

 

Operating Income *

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Surfactants

 

$

33,867

 

 

$

29,148

 

 

 

16

%

 

$

122,780

 

 

$

133,518

 

 

 

(8

)%

Polymers

 

$

11,419

 

 

$

9,510

 

 

 

20

%

 

$

69,567

 

 

$

66,373

 

 

 

5

%

Specialty Products

 

$

5,041

 

 

$

5,118

 

 

 

(2

)%

 

$

16,415

 

 

$

11,661

 

 

 

41

%

Segment Operating Income

 

$

50,327

 

 

$

43,776

 

 

 

15

%

 

$

208,762

 

 

$

211,552

 

 

 

(1

)%

Corporate Expenses

 

$

(21,836

)

 

$

(8,325

)

 

 

162

%

 

$

(81,502

)

 

$

(62,287

)

 

 

31

%

    Consolidated Operating Income

 

$

28,491

 

 

$

35,451

 

 

 

(20

)%

 

$

127,260

 

 

$

149,265

 

 

 

(15

)%

 

* The 2018 Segment operating income amounts have been retrospectively changed from the amounts originally reported as a result of the Company’s first quarter 2019 change in method of accounting for U.S. inventory valuation from LIFO to FIFO.

 

Total segment operating income increased $6.6 million, or 15%, versus the prior year quarter.  Full year segment operating income decreased $2.8 million, or 1%, versus the prior year.    

 

 

Surfactant net sales were $310.0 million for the quarter, a 4% decrease versus the prior year.  Selling prices were down 3% primarily due to the pass-through of lower raw material costs.  The translation impact of a stronger U.S. dollar decreased net sales by 1%.  Sales volume was flat versus the prior year.  Higher global demand for products sold into our agricultural and oil field end markets offset lower sales volume of surfactants to our distribution partners.  Surfactant operating income increased $4.7 million, or 16% versus the prior year, primarily due to insurance recovery related to the Ecatepec, Mexico incident and margin improvement.  These items were partially offset by lower U.S. demand and year end inventory adjustments in the distribution channel and higher unit overhead costs in Singapore due to unfavorable production timing differences.

 

Polymer net sales were $116.4 million in the fourth quarter, down 5% versus prior year.  Total sales volume increased 3% quarter-over-quarter.  Global rigid polyol volume growth of 7% more than offset lower phthalic anhydride volumes.  Selling prices declined 7% and the translation impact of a stronger U.S. dollar negatively impacted net sales by 1%.  Operating income increased $1.9 million, or 20%, versus the prior year quarter primarily due to higher sales volume and a more favorable product mix.  

 

Specialty Product net sales were $18.6 million for the quarter, a 9% decrease versus the prior year.  Sales volume declined 7% for the quarter.  Operating income decreased $0.1 million versus the prior year quarter primarily due to unfavorable order timing differences within our flavor business that were mostly offset by improved margins within our medium chain triglycerides (MCTs) product line.  

 

 

 

 

 

 

 

 

 

 

4


Corporate Expenses

 

 

 

Three Months Ended

December 31

 

 

Twelve Months Ended

December 31

 

($ in thousands)

 

2019

 

 

2018

 

 

%

Change

 

 

2019

 

 

2018

 

 

%

Change

 

Total  -  Corporate Expenses

 

$

21,836

 

 

$

8,325

 

 

 

162

%

 

$

81,502

 

 

$

62,287

 

 

 

31

%

Less:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    Deferred Compensation Expense/(Income) *

 

$

3,662

 

 

$

(7,300

)

 

NM

 

 

$

15,140

 

 

$

(2,329

)

 

NM

 

    Business Restructuring

 

$

1,102

 

 

$

242

 

 

 

355

%

 

$

2,744

 

 

$

2,588

 

 

 

6

%

Adjusted Corporate Expense

 

$

17,072

 

 

$

15,383

 

 

 

11

%

 

$

63,618

 

 

$

62,028

 

 

 

3

%

 

* See Table III for a discussion of deferred compensation plan accounting.

    

Corporate expenses, excluding deferred compensation and business restructuring expenses, increased $1.7 million, or 11%, versus the prior year quarter.  This quarterly increase was primarily due to a $1.3 million pre-tax adjustment to the Company’s environmental remediation reserves associated with the Company’s formerly-owned site in Wilmington, Massachusetts.  

 

 

Income Taxes

 

The Company’s full year effective tax rate was 18.1% in 2019 compared to 19.4% in 2018.  This year-over-year decrease was primarily attributable to higher current year U.S. research and development tax credits, partially offset by the non-recurrence of 2018 favorable tax benefits.  Net interest expense is down 45% year-over-year primarily due to interest earned on higher U.S. cash balances after the cash repatriation completed in 2018.    

 

 

Shareholder Return

 

The Company paid $6.2 million of dividends to shareholders in the fourth quarter of 2019.  For the full year the Company paid $23.1 million of dividends and repurchased $13.2 million of Company stock.  The Company has 349,830 shares remaining under its Board of Directors’ share repurchase authorization.  With the increased cash dividend in the fourth quarter of 2019, the Company has increased its dividend on its common stock for the 52nd consecutive year.

 

 

Selected Balance Sheet Information

 

The Company’s net debt level decreased $39.2 million for the quarter while the net debt ratio decreased from -7% to -12%, reflecting cash balances in excess of total debt.  The decrease in net debt was attributable to a $29.4 million increase in cash, partially driven by lower working capital requirements, and a $9.8 million decline in total debt.  

 

5


($ in millions)

12/31/19

 

 

9/30/19

 

 

6/30/19

 

 

3/31/19

 

 

12/31/18

 

Net Debt

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Debt

$

222.1

 

 

$

231.9

 

 

$

232.6

 

 

$

271.9

 

 

$

276.1

 

Cash

 

315.4

 

 

 

286.0

 

 

 

275.3

 

 

 

269.5

 

 

 

300.2

 

Net Debt

$

(93.3

)

 

$

(54.1

)

 

$

(42.7

)

 

$

2.4

 

 

$

(24.1

)

Equity *

 

891.8

 

 

 

854.2

 

 

 

857.7

 

 

 

831.4

 

 

 

807.4

 

Net Debt + Equity *

$

798.5

 

 

$

800.1

 

 

$

815.0

 

 

$

833.8

 

 

$

783.3

 

Net Debt / (Net Debt + Equity)

 

-12

%

 

 

-7

%

 

 

-5

%

 

 

0

%

 

 

-3

%

 

 

 

The major working capital components were:

 

($ in millions)

12/31/19

 

 

9/30/19

 

 

6/30/19

 

 

3/31/19

 

 

12/31/18

 

Net Receivables

$

276.8

 

 

$

283.0

 

 

$

289.0

 

 

$

298.9

 

 

$

280.0

 

Inventories *

 

203.6

 

 

 

203.3

 

 

 

216.3

 

 

 

215.0

 

 

 

231.5

 

Accounts Payable

 

(194.3

)

 

 

(175.8

)

 

 

(184.7

)

 

 

(175.6

)

 

 

(206.0

)

 

$

286.1

 

 

$

310.5

 

 

$

320.6

 

 

$

338.3

 

 

$

305.5

 

 

* The 2018 amounts for the noted line items have been retrospectively changed from the amounts originally reported as a result of the Company’s first quarter 2019 change in method of accounting for U.S. inventory valuation from LIFO to FIFO.

 

The Company had full year capital expenditures of $105.6 million in 2019 versus $86.6 million in the prior year.

 

 

Millsdale Plant Incident

 

On January 19, 2020, we experienced a power disruption that impacted Millsdale, our largest facility.   Although power was restored after a period of time, the power outage and below freezing temperatures created significant production and operational challenges.   We have been able to run on a partial basis and have used existing inventories to serve our customers. However, on February 17, 2020, operational issues impacted the site’s waste water treatment plant (WWTP) and forced us to stop production at the site.   We have been able to restart Polyol production using a temporary solution and are targeting to bring the WWTP back into operation within the next few days.   Once the WWTP is operational, we expect that production of Surfactants will resume. We anticipate Phthalic Anhydride production will remain down for approximately 30 days.  Because of the WWTP being down and low inventory levels, we have declared Force Majeure for the supply of Phthalic Anhydride and certain Surfactant product lines.  We are using our global production network and working with customers to minimize this supply disruption.  We are also working with our insurance provider to recover the losses related to this incident.      

 

At this time, we are not able to quantify the extent of the impact from this event, but this incident creates a challenge for us in 2020.  We are confident that the resources are in place to resolve the issue and move forward.  For more than 80 years we have supplied our customers on a reliable basis and are committed to do so in the future.  

 

2020 Outlook

 

Although we anticipate a very challenging first quarter, we believe our continued focus on end market diversification, Tier 2 and Tier 3 customers, as well as our cost-out activities

6


should benefit our Surfactant business. We believe energy conservation efforts around the world will support our Polymer business and volume should continue to grow. We anticipate our Specialty Products business results will approximate 2019. Additional headwinds include the potential negative impact of Coronavirus in China, as well as higher raw material sourcing costs due to Illinois River lock closures scheduled during the second half of 2020.

 

Conference Call

 

Stepan Company will host a conference call to discuss its fourth quarter and full year 2019 results at 10:00 a.m. ET (9:00 a.m. CT) on February 20, 2020. The call can be accessed by phone and webcast. Telephone access will be available by dialing +1 (800) 931-6421, and the webcast can be accessed through the Investor Relations/Conference Calls page at www.stepan.com. A webcast replay of the conference call will be available at the same location shortly after the call.

 

Supporting Slides

 

Slides supporting this press release will be made available at www.stepan.com through the Investor Relations page at approximately the same time as this press release is issued.

 

Corporate Profile

 

Stepan Company is a major manufacturer of specialty and intermediate chemicals used in a broad range of industries.  Stepan is a leading merchant producer of surfactants, which are the key ingredients in consumer and industrial cleaning compounds and in agricultural and oilfield solutions.  The Company is also a leading supplier of polyurethane polyols used in the expanding thermal insulation market, and CASE (Coatings, Adhesives, Sealants, and Elastomers) industries.

 

Headquartered in Northfield, Illinois, Stepan utilizes a network of modern production facilities located in North and South America, Europe and Asia.

 

The Company’s common stock is traded on the New York Stock Exchange (NYSE) under the symbol SCL.  For more information about Stepan Company please visit the Company online at www.stepan.com

 

 

Contact: Luis E. Rojo                              (847) 446-7500

 

* * * * *

 

Tables follow

 

Certain information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements about Stepan Company’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, Stepan Company’s actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “guidance,” “predict,” “potential,” “continue,” “likely,” “will,” “would,” ”should,” “illustrative” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered

7


reasonable by Stepan Company and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements.

There are a number of risks, uncertainties and other important factors, many of which are beyond Stepan Company’s control, that could cause actual results to differ materially from the forward-looking statements contained in this news release. Such risks, uncertainties and other important factors include, among other factors, the risks, uncertainties and factors described in Stepan Company’s Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports, and include (but are not limited to) risks and uncertainties related to disruptions in production or accidents at manufacturing facilities, global competition, volatility of raw material and energy costs, disruptions in transportation or significant changes in transportation costs, reduced demand due to customer product reformulations or new technologies, the probability of future acquisitions and the uncertainties related to the integration of acquired businesses, maintaining and protecting intellectual property rights, international business risks, including currency exchange rate fluctuations, legal restrictions and taxes, our debt covenants, our ability to access capital markets, downturns in certain industries and general economic downturns, global political, military, security or other instability, costs related to expansion or other capital projects, interruption or breaches of information technology systems, the costs and other effects of governmental regulation and legal and administrative proceedings and our ability to retain executive management and key personnel.

These forward-looking statements are made only as of the date hereof, and Stepan Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

 


8


Table I

STEPAN COMPANY

For the Three and Twelve Months Ended December 31, 2019 and 2018

(Unaudited – in thousands, except per share data)

 

 

 

Three Months Ended

December 31

 

 

Twelve Months Ended

December 31

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Net Sales

 

$

444,990

 

 

$

466,659

 

 

$

1,858,745

 

 

$

1,993,857

 

Cost of Sales *

 

 

360,246

 

 

 

392,065

 

 

 

1,519,031

 

 

 

1,654,508

 

Gross Profit *

 

 

84,744

 

 

 

74,594

 

 

 

339,714

 

 

 

339,349

 

Operating Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling

 

 

14,661

 

 

 

13,447

 

 

 

56,956

 

 

 

56,319

 

Administrative

 

 

22,019

 

 

 

19,802

 

 

 

82,577

 

 

 

79,243

 

Research, Development and Technical Services

 

 

14,809

 

 

 

12,952

 

 

 

55,037

 

 

 

54,263

 

Deferred Compensation (Income) Expense

 

 

3,662

 

 

 

(7,300

)

 

 

15,140

 

 

 

(2,329

)

 

 

 

55,151

 

 

 

38,901

 

 

 

209,710

 

 

 

187,496

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Business Restructuring

 

 

1,102

 

 

 

242

 

 

 

2,744

 

 

 

2,588

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Income *

 

 

28,491

 

 

 

35,451

 

 

 

127,260

 

 

 

149,265

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest, Net

 

 

(911

)

 

 

(2,151

)

 

 

(5,932

)

 

 

(10,771

)

Other, Net

 

 

306

 

 

 

(2,715

)

 

 

4,571

 

 

 

(725

)

 

 

 

(605

)

 

 

(4,866

)

 

 

(1,361

)

 

 

(11,496

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income Before Income Taxes *

 

 

27,886

 

 

 

30,585

 

 

 

125,899

 

 

 

137,769

 

Provision for Income Taxes *

 

 

5,853

 

 

 

6,631

 

 

 

22,798

 

 

 

26,664

 

Net Income *

 

 

22,033

 

 

 

23,954

 

 

 

103,101

 

 

 

111,105

 

Net (Income) Loss Attributable to Noncontrolling Interests

 

 

5

 

 

 

3

 

 

 

28

 

 

 

12

 

Net Income Attributable to Stepan Company *

 

$

22,038

 

 

$

23,957

 

 

$

103,129

 

 

$

111,117

 

Net Income Per Common Share Attributable to Stepan Company *

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic *

 

$

0.96

 

 

$

1.04

 

 

$

4.47

 

 

$

4.83

 

Diluted *

 

$

0.95

 

 

$

1.03

 

 

$

4.42

 

 

$

4.76

 

Shares Used to Compute Net Income Per Common

Share Attributable to Stepan Company

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

23,005

 

 

 

22,987

 

 

 

23,054

 

 

 

23,022

 

Diluted

 

 

23,302

 

 

 

23,330

 

 

 

23,316

 

 

 

23,325

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

* The 2018 amounts for the noted line items have been retrospectively changed from the amounts originally reported as a result of the Company’s first quarter 2019 change in method of accounting for U.S. inventory valuation from LIFO to FIFO.

9


Table II

 

 

Reconciliation of Non-GAAP Net Income and Earnings per Diluted Share *

 

 

 

Three Months Ended

December 31

 

 

Twelve Months Ended

December 31

 

($ in thousands, except per share amounts)

 

2019

 

 

EPS

 

 

2018                        As Adjusted

 

 

EPS                        As Adjusted

 

 

2019

 

 

EPS

 

 

2018                        As Adjusted

 

 

EPS                        As Adjusted

 

Net Income Reported

 

$

22,038

 

 

$

0.95

 

 

$

23,957

 

 

$

1.03

 

 

$

103,129

 

 

$

4.42

 

 

$

111,117

 

 

$

4.76

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred Compensation (Income) Expense

 

$

1,465

 

 

$

0.06

 

 

$

(3,420

)

 

$

(0.15

)

 

$

7,947

 

 

$

0.34

 

 

$

(787

)

 

$

(0.03

)

Business Restructuring

 

$

806

 

 

$

0.04

 

 

$

182

 

 

$

0.01

 

 

$

2,005

 

 

$

0.09

 

 

$

1,842

 

 

$

0.08

 

Cash-Settled SARs (Income) Expense

 

$

325

 

 

$

0.01

 

 

$

(1,237

)

 

$

(0.05

)

 

$

2,090

 

 

$

0.09

 

 

$

(520

)

 

$

(0.02

)

Environmental Remediation

 

$

1,058

 

 

$

0.04

 

 

$

-

 

 

$

-

 

 

$

3,268

 

 

$

0.14

 

 

$

-

 

 

$

-

 

Voluntary Debt Prepayment

 

$

-

 

 

$

-

 

 

$

-

 

 

$

-

 

 

$

948

 

 

$

0.04

 

 

$

-

 

 

$

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted Net Income

 

$

25,692

 

 

$

1.10

 

 

$

19,482

 

 

$

0.84

 

 

$

119,387

 

 

$

5.12

 

 

$

111,652

 

 

$

4.79

 

 

* All amounts in this table are presented after-tax

 

The Company believes that certain measures that are not in accordance with generally accepted accounting principles (GAAP), when presented in conjunction with comparable GAAP measures, are useful for evaluating the Company’s operating performance and provide better clarity on the impact of non-operational items.  Internally, the Company uses this non-GAAP information as an indicator of business performance, and evaluates management’s effectiveness with specific reference to these indicators.  These measures should be considered in addition to, and are neither a substitute for, nor superior to, measures of financial performance prepared in accordance with GAAP.

 

Reconciliation of Pre-Tax to After-Tax Adjustments

 

 

 

Three Months Ended

December 31

 

 

Twelve Months Ended

December 31

 

($ in thousands, except per share amounts)

 

2019

 

 

EPS

 

 

2018

 

 

EPS

 

 

2019

 

 

EPS

 

 

2018

 

 

EPS

 

Pre-Tax Adjustments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred Compensation (Income) Expense

 

$

1,927

 

 

 

 

 

 

$

(4,500

)

 

 

 

 

 

$

10,456

 

 

 

 

 

 

$

(1,035

)

 

 

 

 

Business Restructuring

 

$

1,102

 

 

 

 

 

 

$

242

 

 

 

 

 

 

$

2,744

 

 

 

 

 

 

$

2,588

 

 

 

 

 

Cash-Settled SARs (Income) Expense

 

$

427

 

 

 

 

 

 

$

(1,628

)

 

 

 

 

 

$

2,749

 

 

 

 

 

 

$

(685

)

 

 

 

 

Environmental Remediation

 

$

1,392

 

 

 

 

 

 

$

-

 

 

 

 

 

 

$

4,300

 

 

 

 

 

 

$

-

 

 

 

 

 

Voluntary Debt Prepayment

 

$

-

 

 

 

 

 

 

$

-

 

 

 

 

 

 

$

1,247

 

 

 

 

 

 

$

-

 

 

 

 

 

   Total Pre-Tax Adjustments

 

$

4,848

 

 

 

 

 

 

$

(5,886

)

 

 

 

 

 

$

21,496

 

 

 

 

 

 

$

868

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cumulative Tax Effect on Adjustments

 

$

(1,194

)

 

 

 

 

 

$

1,411

 

 

 

 

 

 

$

(5,238

)

 

 

 

 

 

$

(333

)

 

 

 

 

US Tax Reform Impact

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

After-Tax Adjustments

 

$

3,654

 

 

$

0.15

 

 

$

(4,475

)

 

$

(0.19

)

 

$

16,258

 

 

$

0.70

 

 

$

535

 

 

$

0.03

 

10


Table III

 

 

Deferred Compensation Plan

 

 

The full effect of the deferred compensation plan on quarterly pretax income was $1.9 million of expense versus $4.5 million of income in the prior year.  The year-to-date impact was $10.5 million of expense versus $1.0 million of income in the prior year. The accounting for the deferred compensation plan results in operating income when the price of Stepan Company common stock or mutual funds held in the plan fall and expense when they rise.  The Company also recognizes the change in value of mutual funds as investment income or loss.  The quarter end market prices of Stepan Company common stock are as follows:

 

 

2019

 

 

2018

 

 

 

12/31

 

 

9/30

 

 

6/30

 

 

3/31

 

 

12/31

 

 

9/30

 

 

6/30

 

 

3/31

 

Stepan Company

 

$

102.44

 

 

$

97.06

 

 

$

91.91

 

 

$

87.52

 

 

$

74.00

 

 

$

87.01

 

 

$

78.01

 

 

$

83.18

 

 

 

The deferred compensation income statement impact is summarized below:

 

 

Three Months Ended

December 31

 

 

Twelve Months Ended

December 31

 

($ in thousands)

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Deferred Compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Income (Expense)

 

$

(3,662

)

 

$

7,300

 

 

$

(15,140

)

 

$

2,329

 

Other, net – Mutual Fund Gain (Loss)

 

 

1,735

 

 

 

(2,800

)

 

 

4,684

 

 

 

(1,294

)

Total Pretax

 

$

(1,927

)

 

$

4,500

 

 

$

(10,456

)

 

$

1,035

 

Total After Tax

 

$

(1,465

)

 

$

3,420

 

 

$

(7,947

)

 

$

787

 

 

 

 

 


11


Table IV

 

 

Effects of Foreign Currency Translation

 

The Company’s foreign subsidiaries transact business and report financial results in their respective local currencies. As a result, foreign subsidiary income statements are translated into U.S. dollars at average foreign exchange rates appropriate for the reporting period. Because foreign currency exchange rates fluctuate against the U.S. dollar over time, foreign currency translation affects period-to-period comparisons of financial statement items (i.e., because foreign exchange rates fluctuate, similar period-to-period local currency results for a foreign subsidiary may translate into different U.S. dollar results).  The table below presents the impact that foreign currency translation had on the changes in consolidated net sales and various income line items for the three and twelve month periods ending December 31, 2019 as compared to 2018:

 

($ in millions)

 

Three Months Ended

December 31

 

 

Increase (Decrease)

 

 

Change

Due to Foreign

Currency

Translation

 

 

Twelve Months Ended

December 31

 

 

Increase

(Decrease)

 

 

Change

Due to Foreign

Currency

Translation

 

 

 

2019

 

 

2018

 

 

 

 

 

 

 

 

 

 

2019

 

 

2018

 

 

 

 

 

 

 

 

 

Net Sales

 

$

445.0

 

 

$

466.7

 

 

$

(21.7

)

 

$

(4.1

)

 

$

1,858.7

 

 

$

1,993.9

 

 

$

(135.2

)

 

$

(37.3

)

Gross Profit *

 

 

84.7

 

 

 

74.6

 

 

 

10.1

 

 

 

(0.4

)

 

 

339.7

 

 

 

339.3

 

 

 

0.4

 

 

 

(5.0

)

Operating Income *

 

 

28.5

 

 

 

35.5

 

 

 

(7.0

)

 

 

-

 

 

 

127.3

 

 

 

149.3

 

 

 

(22.0

)

 

 

(2.5

)

Pretax Income *

 

 

27.9

 

 

 

30.6

 

 

 

(2.7

)

 

 

-

 

 

 

125.9

 

 

 

137.8

 

 

 

(11.9

)

 

 

(2.4

)

 

* The 2018 amounts for the noted line items have been retrospectively changed from the amounts originally reported as a result of the Company’s first quarter 2019 change in method of accounting for U.S. inventory valuation from LIFO to FIFO.

 

 

 


12


Table V

 

 

Stepan Company

Consolidated Balance Sheets

December 31, 2019 and December 31, 2018

 

 

December 31, 2019

 

 

December 31, 2018 As Adjusted

 

ASSETS

 

 

 

 

 

 

 

 

Current Assets *

 

$

818,789

 

 

$

833,893

 

Property, Plant & Equipment, Net

 

 

639,317

 

 

 

608,892

 

Other Assets

 

 

121,261

 

 

 

71,829

 

Total Assets *

 

$

1,579,367

 

 

$

1,514,614

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current Liabilities

 

$

339,114

 

 

$

338,582

 

Deferred Income Taxes *

 

 

23,391

 

 

 

24,961

 

Long-term Debt

 

 

198,532

 

 

 

239,022

 

Other Non-current Liabilities

 

 

125,834

 

 

 

103,864

 

Total Stepan Company Stockholders’ Equity *

 

 

891,783

 

 

 

807,425

 

Noncontrolling Interest

 

 

713

 

 

 

760

 

Total Liabilities and Stockholders’ Equity *

 

$

1,579,367

 

 

$

1,514,614

 

 

* The 2018 amounts for the noted line items have been retrospectively changed from the amounts originally reported as a result of the Company’s first quarter 2019 change in method of accounting for U.S. inventory valuation from LIFO to FIFO.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

13